Tag: Medicine and Dentistry Award

Waseem AlZamzami | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Assoc. Prof. Dr. Waseem AlZamzami | Medicine and Dentistry | Best Researcher Award

University of Tabuk, Saudi Arabia

Assoc. Prof. Dr. Waseem A. AlZamzami is an accomplished researcher and academic in hematopathology, molecular hematology, and cancer biology, with a strong focus on genomics, transcriptomics, metabolomics, and bioinformatics. He earned his Ph.D. in Clinical Laboratory Science from The Catholic University of America, Washington DC (2015–2022), following an M.S. in Health Sciences from Quinnipiac University, Connecticut (2013–2015), and a B.Sc. in Laboratory Medicine from Umm Al-Qurra University, Saudi Arabia (2002–2006). His professional journey includes extensive research training at the National Cancer Institute/National Institutes of Health (NCI/NIH), Bethesda, USA, where he contributed to advancing cancer genetics and translational hematology. Currently serving as an Assistant Professor of Hematology at the University of Tabuk, Saudi Arabia, he has held multiple leadership roles such as Committee Chairman for Laboratory Management, Unit Chairman for Measurement and Evaluation, and active member of Accreditation, Quality Assurance, and Curriculum Development committees. His research interests center on genetic screening, biomarker discovery, and integration of multi-omics to drive precision oncology and personalized treatment strategies. Dr. AlZamzami has authored publications in reputed journals including Discovery Medicine, Molecular Syndromology, PLOS ONE, and Cancers, with a Scopus record of 9 documents, 36 citations, and an h-index of 3, alongside three recent Saudi patents in hematological malignancies and cancer genomics. He is also a dedicated reviewer for journals such as PLOS ONE, Process Biochemistry, and International Immunopharmacology. His research skills span molecular diagnostics, bioinformatics, laboratory medicine, multi-omics analysis, and translational applications bridging bench to bedside. Recognized through international symposium presentations at NIH and national scientific forums, he has also contributed to scientific community development by mentoring students and organizing academic events. In conclusion, Dr. Waseem A. AlZamzami exemplifies a distinguished researcher whose academic excellence, innovative research, and leadership contributions to cancer biology and hematology strongly position him as a driving force in advancing precision medicine and biomedical research globally.

Profile: Scopus |ORCID| Google Scholar

Featured Publications

  1. Yan, H., Malik, N., Kim, Y. I., He, Y., Li, M., Dubois, W., Liu, H., Peat, T. J., Nguyen, J. T., … (2021). Fatty acid oxidation is required for embryonic stem cell survival during metabolic stress. EMBO Reports, 22(6), e52122.

  2. Oyouni, A. A. A., Al-Amer, O. M., Ali, F. A. Z., Altayar, M. A., Jalal, M. M., Albalawi, R. S. M., … (2022). Melatonin ameliorates the adrenal and pancreatic alterations in streptozotocin-induced diabetic rats: Clinical, biochemical, and descriptive histopathological studies. Frontiers in Veterinary Science, 9, 1016312.

  3. Seshadri, V. D., Oyouni, A. A. A., Hawsawi, Y. M., Aljohani, S. A. S., Al-Amer, O. M., … (2022). Chemopreventive role of Tin oxide–Chitosan–Polyethylene glycol–Crocin nanocomposites against lung cancer: An in vitro and in vivo approach. Process Biochemistry, 120, 186–194.

  4. Al-Amer, O. M., Mir, R., Hamadi, A., Alasseiri, M. I., Altayar, M. A., AlZamzami, W., … (2023). Antiapoptotic gene genotype and allele variations and the risk of lymphoma. Cancers, 15(4), 1012.

  5. Vijayaragavan, P., Rathi, M. A., Gopalakrishnan, V. K., Pashameah, R. A., … (2022). CpG methylation analysis of tumour suppressor gene and expression of cathepsin B in renal cell carcinoma. Journal of King Saud University – Science, 34(8), 102330.

Alexey Fayzullin | Medicine and Dentistry | Pioneer Researcher Award

Published on by WSA Awards

Dr. Alexey Fayzullin | Medicine and Dentistry | Pioneer Researcher Award

Sechenov University, Russia

Dr. Alexey Fayzullin, PhD, MD, is a distinguished medical scientist specializing in regenerative medicine, computational pathology, and digital biomedical technologies, with a strong academic and research foundation at Sechenov University, Russia. He completed his general medical studies at the International School “Medicine of the Future” (2011–2017) and earned his PhD in anatomical pathology in 2022, with a thesis on antifibrotic scaffolds in regenerative medicine. His professional journey began as a laboratory assistant (2018–2019) and junior researcher (2019–2023) in the Laboratory of Experimental Morphology at the Institute for Regenerative Medicine, before advancing to Head of the Laboratory of Digital Microscopic Analysis in 2023. His research interests span tissue engineering, artificial intelligence in histological image analysis, cell therapy, biophotonics, implantology, and computational biomedicine. With 47 peer-reviewed publications, 626 citations, and an h-index of 12, Dr. Fayzullin has contributed significantly to scientific knowledge, with his works appearing in internationally recognized journals and conferences. His research experience includes prestigious internships at Macquarie University and the University of New South Wales, where he collaborated on advanced bioengineering projects. He has won multiple competitive grants and awards, including several Russian Presidential Scholarships for international research, grants from the Russian Science Foundation (RSF) and Russian Foundation for Basic Research (RFBR), and the establishment of his own laboratory under the Priority 2030 program. His skills include advanced digital microscopy, AI-based image processing, regenerative scaffold design, project leadership, and academic mentoring. As an educator, he has co-authored Russia’s first regenerative medicine handbook, designed specialized academic courses, and supervises PhD and undergraduate students. Dr. Fayzullin’s honors, leadership roles, and international collaborations highlight his impact on both science and education. In conclusion, his remarkable achievements, innovative research, and commitment to biomedical advancement demonstrate why he is an emerging leader with the potential to shape the future of global regenerative medicine and digital healthcare.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Valieva, Y., Ivanova, E., Fayzullin, A., Kurkov, A., & Igrunkova, A. (2022). Senescence-associated β-galactosidase detection in pathology. Diagnostics, 12(10), 2309. Cited 146 times

Shekhter, A. B., Fayzullin, A. L., Vukolova, M. N., Rudenko, T. G., Osipycheva, V. D., & Litvitsky, P. F. (2019). Medical applications of collagen and collagen-based materials. Current Medicinal Chemistry, 26(3), 506–516. Cited 129 times

Deng, W., McKelvey, K. J., Guller, A., Fayzullin, A., Campbell, J. M., Clement, S., & Saunders, C. M. (2020). Application of mitochondrially targeted nanoconstructs to neoadjuvant X-ray-induced photodynamic therapy for rectal cancer. ACS Central Science, 6(5), 715–726. Cited 88 times

Fayzullin, A., Bakulina, A., Mikaelyan, K., Shekhter, A., & Guller, A. (2021). Implantable drug delivery systems and foreign body reaction: Traversing the current clinical landscape. Bioengineering, 8(12), 205. Cited 73 times

Fayzullin, A., Churbanov, S., Ignatieva, N., Zakharkina, O., Tokarev, M., & Shekhter, A. (2021). Local delivery of pirfenidone by PLA implants modifies foreign body reaction and prevents fibrosis. Biomedicines, 9(8), 853. Cited 35

Shekhter, A. B., Pekshev, A. V., Vagapov, A. B., Telpukhov, V. I., Panyushkin, P. V., Fayzullin, A. L., & Vanin, A. F. (2019). Physicochemical parameters of NO-containing gas flow affect wound healing therapy: An experimental study. European Journal of Pharmaceutical Sciences, 128, 193–201. Cited 34

Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Dr. Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Mary Bird Perkins Cancer Center | United States

Dr. Sotirios Stathakis is an accomplished medical physicist with extensive experience in radiation oncology, advanced treatment planning, and patient safety in cancer care. Currently serving as the Chief of Physics at Mary Bird Perkins Cancer Center and Adjunct Professor at Louisiana State University, he has established himself as a leader in both clinical and academic domains. His work bridges fundamental research and real-world clinical application, focusing on improving the accuracy, efficiency, and safety of radiotherapy treatments. With a career spanning over two decades, Dr. Stathakis has played a pivotal role in advancing technologies such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), Monte Carlo simulations, and adaptive radiotherapy. He has supervised graduate students, medical residents, and postdoctoral fellows, contributing to the development of the next generation of medical physicists. Dr. Stathakis is internationally recognized for his innovative contributions to medical physics, publishing widely in peer-reviewed journals and presenting at global conferences. His leadership in quality assurance (QA) protocols, radiotherapy safety standards, and patient-centered innovations has earned him professional recognition as a Fellow of the American Association of Physicists in Medicine (AAPM). He continues to expand his research by integrating artificial intelligence, patient education, and wearable technology into cancer care.

Professional Profile

Scopus | ORCID

Education

Dr. Sotirios Stathakis has a strong academic background rooted in physics and medical physics, which forms the foundation of his distinguished career in cancer treatment and research. He began his academic journey with a Bachelor of Science in Physics from the University of Waterloo, Canada, where he developed a strong foundation in core physical sciences and problem-solving skills. Driven by an interest in applying physics to medicine, he pursued a Master of Science in Medical Physics at the University of Aberdeen, United Kingdom. Here, he received specialized training in radiological sciences, medical imaging, and radiotherapy applications, which fueled his passion for research in patient care. His academic progression culminated in a Ph.D. in Medical Physics from the University of Patras, Greece, where his doctoral work focused on advanced radiation dosimetry and optimization of treatment planning systems. His doctoral training allowed him to explore Monte Carlo simulations and radiation safety protocols, which later became key aspects of his professional contributions. This comprehensive education, spanning North America and Europe, equipped him with a unique global perspective and multidisciplinary expertise. It also prepared him to integrate clinical practice with research, ultimately shaping his career as a recognized leader in medical physics and radiation oncology.

Professional Experience

Dr. Sotirios Stathakis has accumulated diverse professional experience that reflects his dual commitment to academic research and clinical application. He began his career in Europe, contributing to medical physics research before moving to the United States, where he established himself in leading academic and clinical institutions. At the University of Texas Health Science Center San Antonio (UTHSA), he served as a Professor and Medical Physicist, taking on responsibilities that included treatment planning, clinical implementation of new radiotherapy techniques, and the supervision of graduate students and medical residents. His academic contributions included teaching advanced courses in radiation oncology physics and mentoring Ph.D. dissertations. He later transitioned to his current role as Chief of Physics at Mary Bird Perkins Cancer Center, where he oversees medical physics operations across multiple oncology centers. In this role, he leads a team of physicists and ensures the safe and effective delivery of radiation treatments to cancer patients. His position as Adjunct Professor at Louisiana State University complements his clinical work, as he continues to teach and mentor the next generation of medical physicists. Throughout his career, Dr. Stathakis has balanced leadership, clinical service, and research, contributing to advancements in both patient care and academic knowledge.

Research Interests

Dr. Sotirios Stathakis’s research interests lie at the intersection of clinical innovation, radiation therapy optimization, and patient-centered approaches. A central focus of his research is the improvement of treatment planning systems, particularly through advanced modeling such as Monte Carlo simulations, which enhance accuracy in dose calculations. He has contributed to the development and refinement of quality assurance (QA) protocols, ensuring precision in intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). Another important area of his research includes studying the secondary cancer risks associated with radiotherapy, providing valuable insights into long-term patient safety. Dr. Stathakis is also exploring the role of artificial intelligence (AI) in radiotherapy, particularly for dose prediction and workflow optimization, which has the potential to revolutionize clinical practices. In recent years, he has expanded his focus to include patient-centered technologies, such as wearable monitoring devices and virtual reality tools that improve patient education, engagement, and treatment compliance. His interdisciplinary approach combines physics, engineering, computer science, and clinical oncology, creating innovative solutions to complex healthcare challenges. By bridging these fields, Dr. Stathakis continues to advance the standards of radiotherapy, contributing to safer, more effective, and personalized cancer treatments.

Research Skills

Dr. Sotirios Stathakis possesses a broad range of research skills that span computational modeling, experimental validation, clinical trial design, and academic mentoring. His expertise in Monte Carlo simulations allows him to perform highly accurate radiation dose calculations, a critical aspect of treatment planning and safety assessment in radiation oncology. He is also highly skilled in advanced quality assurance techniques, particularly for IMRT and VMAT, ensuring reliable and precise delivery of radiation therapy. Dr. Stathakis is proficient in using and commissioning treatment planning systems and linear accelerators, applying both theoretical and practical approaches to improve clinical workflows. His research methodology incorporates statistical analysis, machine learning, and artificial intelligence, enabling him to address complex problems in treatment optimization and patient safety. Beyond technical skills, he excels in collaborative project management, coordinating interdisciplinary teams across physics, medicine, and engineering. His experience extends to academic publishing, peer review, and conference presentations, reflecting his ability to effectively disseminate scientific findings. As a mentor and educator, he has guided Ph.D. students and medical residents in developing independent research projects, further demonstrating his leadership in research environments. Collectively, these skills highlight his ability to translate advanced scientific concepts into practical innovations that benefit cancer patients worldwide.

Awards and Honors

Throughout his career, Dr. Sotirios Stathakis has received numerous awards and honors in recognition of his academic excellence, clinical leadership, and professional service. One of the most prestigious distinctions in his career is being named a Fellow of the American Association of Physicists in Medicine (AAPM), a recognition reserved for members who have made significant contributions to the advancement of medical physics. He is also board-certified in Therapeutic Radiologic Physics by the American Board of Radiology (ABR), underscoring his professional expertise and credibility in clinical practice. His academic work has been acknowledged through invitations to present at leading international conferences, including those organized by IEEE, AAPM, and ESTRO, where he has shared groundbreaking findings on radiotherapy optimization and quality assurance. In addition, Dr. Stathakis has served as a peer reviewer for high-impact journals such as the Journal of Applied Clinical Medical Physics (JACMP), further highlighting his standing in the scientific community. He has also been recognized by institutions where he has taught and worked, receiving commendations for excellence in mentorship and clinical service. These honors reflect his consistent commitment to innovation, patient safety, and education, solidifying his reputation as a respected leader in medical physics and radiation oncology.

Publication Top Notes

  • AAPM TG report 312: Acceptance testing, commissioning, and periodic quality assurance of ion chamber and diode detector arrays — 2025

  • Dosimetric characterization of a new surface-conforming electron MLC prototype — 2024 — 1 citation

  • Monte Carlo modeling of the Elekta Versa HD and patient dose calculation with EGSnrc/BEAMnrc — 2022 — 5 citations

  • Erratum to: Report of AAPM Task Group 219 on independent calculation-based dose/MU verification for IMRT — 2021

  • Artificial intelligence based deconvolving on megavoltage photon beam profiles for radiotherapy applications — 2022

  • A customizable aluminum compensator system for total body irradiation — 2021

Conclusion

Dr. Sotirios Stathakis’s career represents a remarkable combination of academic excellence, clinical innovation, and professional leadership. His work has transformed multiple aspects of radiation oncology, from enhancing treatment planning accuracy to implementing robust quality assurance protocols that safeguard patient outcomes. With a strong foundation in education from top institutions across Canada, the United Kingdom, and Greece, coupled with his leadership roles in the United States, he exemplifies the global nature of medical physics. His research interests and skills reflect both scientific rigor and compassion, as he continually integrates patient-centered approaches into his innovations. Recognized internationally through awards, honors, and professional certifications, Dr. Stathakis has established himself as a trusted authority in his field. His mentorship of students and collaboration with clinicians ensure that his influence extends beyond his individual achievements, shaping the future of cancer care. Looking ahead, his engagement with artificial intelligence, wearable technology, and advanced radiotherapy models positions him to make further groundbreaking contributions. In sum, Dr. Stathakis embodies the qualities of a dedicated researcher, educator, and clinician, making him not only a leader in medical physics but also a driving force in advancing the fight against cancer globally.

Hau Xuan Nguyen | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Assist. Prof. Dr. Hau Xuan Nguyen | Medicine and Dentistry | Best Researcher Award

Hanoi Medical University | Vietnam

Assist. Prof. Dr. Hau Xuan Nguyen is a renowned oncologist and surgical innovator from Vietnam, currently serving as Vice Director of the Oncology Center at Hanoi Medical University Hospital and Associate Professor of Medicine at Hanoi Medical University. With over a decade of experience in oncology and surgical oncology, he has made pioneering contributions to cancer diagnosis and treatment, particularly in head, neck, thyroid, and breast cancers. Assist. Prof. Dr. Hau Xuan Nguyen has significantly advanced minimally invasive surgical techniques, notably the transoral endoscopic thyroidectomy vestibular approach (TOETVA), which has improved patient outcomes and reduced post-surgical complications. His expertise spans clinical oncology, surgical oncology, and palliative care, making him a multifaceted leader in both academic and clinical domains. In addition to his clinical roles, he is an accomplished researcher and educator, having published extensively in national and international journals indexed in Scopus, PubMed, and Web of Science. Assist. Prof. Dr. Hau Xuan Nguyen has co-authored over 80 peer-reviewed articles and several influential medical textbooks, contributing to the academic growth of oncology in Vietnam. His research has gained international recognition through collaborations with leading institutions in Ireland, South Korea, and Japan. Assist. Prof. Dr. Hau Xuan Nguyen dedication to patient care, medical research, and surgical innovation underscores his role as a driving force in global oncology.

Professional Profile

Scopus

Education

Assist. Prof. Dr. Hau Xuan Nguyen academic journey reflects a steady progression of excellence and commitment to oncology and surgical innovation. He began his medical career at Hanoi Medical University, where he earned his degree as a General Practitioner. His keen interest in oncology led him to pursue residency training in Oncology at the same institution, equipping him with strong foundations in cancer management. He later advanced his training internationally, undertaking a surgical oncology fellowship at Beaumont Hospital, Royal College of Surgeons in Ireland, where he gained exposure to global practices in cancer surgery. Further strengthening his expertise, he completed another fellowship at the Thyroid Cancer Center, Yonsei University Hospital, South Korea, specializing in innovative thyroid cancer treatments. Assist. Prof. Dr. Hau Xuan Nguyen pursued his Ph.D. in Oncology at Hanoi Medical University, during which he developed expertise in cancer biology, surgical techniques, and clinical research. He achieved the distinguished title of Associate Professor of Medicine in Oncology, affirming his academic leadership. His comprehensive education, both domestic and international, has provided him with a unique blend of clinical excellence, research capability, and surgical innovation, preparing him to serve as a leader in oncology in Vietnam and globally.

Professional Experience

Over the course of his career, Assist. Prof. Dr. Hau Xuan Nguyen has held multiple academic and clinical positions that highlight his leadership and expertise in oncology. he has served as a Lecturer at the Department of Oncology, Hanoi Medical University, where he has trained and mentored the next generation of oncologists. His dedication to clinical practice is evident in his role as a Surgeon at the Department of Oncology and Palliative Care, Hanoi Medical University Hospital, where he provides direct care to cancer patients with complex conditions. Assist. Prof. Dr. Hau Xuan Nguyen was appointed Vice Director of the Oncology Center at Hanoi Medical University Hospital, a prestigious leadership role where he oversees cancer treatment strategies, clinical innovations, and patient care management. Alongside his teaching and clinical responsibilities, he has played a key role in developing advanced surgical practices in Vietnam, particularly in minimally invasive cancer surgery. His leadership extends beyond clinical practice, as he has contributed significantly to academic publishing, national cancer treatment guidelines, and research collaborations. Through his multifaceted professional career, Assist. Prof. Dr. Hau Xuan Nguyen has established himself as a leading figure in oncology, balancing patient care, surgical innovation, teaching, and global research collaborations.

Research Interests

Assist. Prof. Dr. Hau Xuan Nguyen research interests lie at the intersection of surgical oncology, cancer diagnosis, and innovative treatment approaches. His primary focus is on thyroid cancer, head and neck cancers, breast cancer, and gastrointestinal malignancies, where he explores advanced surgical interventions and minimally invasive procedures to improve treatment outcomes. One of his notable areas of expertise is the transoral endoscopic thyroidectomy vestibular approach (TOETVA), a pioneering surgical technique that offers a scar-free solution and reduces post-operative morbidity. He has also conducted extensive research on sentinel lymph node biopsy in thyroid carcinoma, contributing valuable findings to the improvement of surgical staging and treatment planning in oncology. Beyond surgery, Assist. Prof. Dr. Hau Xuan Nguyen is interested in multidisciplinary cancer care, integrating surgery, chemotherapy, targeted therapies, and palliative care to achieve holistic patient management. His publications also reflect a strong commitment to clinical trials, case reports, and molecular studies that provide insights into genetic mutations and their role in cancer progression. Additionally, he has collaborated internationally on studies involving endoscopic and robotic surgical techniques. Through these research interests, Assist. Prof. Dr. Hau Xuan Nguyen is shaping both clinical practice and academic discourse in oncology, with a vision of advancing precision medicine and minimally invasive cancer treatment worldwide.

Research Skills

Assist. Prof. Dr. Hau Xuan Nguyen possesses a comprehensive set of research skills that combine clinical expertise with rigorous scientific methodology. He is highly skilled in designing and conducting clinical trials, particularly those assessing surgical techniques and oncological outcomes. His expertise in endoscopic and minimally invasive surgery has allowed him to contribute to international literature on advanced surgical oncology, with publications in high-impact journals such as Surgical Endoscopy, Oral Oncology, and Journal of Thyroid Research. Assist. Prof. Dr. Hau Xuan Nguyen has strong proficiency in oncological pathology analysis, molecular diagnostics, and cancer genetics, demonstrated by his work on identifying genetic mutations related to breast, thyroid, and colorectal cancers. His ability to use advanced surgical techniques, including robotic and transoral procedures, underscores his practical research contributions. In addition, he has authored six textbooks on oncology and cancer surgery, reflecting his ability to translate research into academic resources for students and practitioners. He also has extensive experience in academic publishing, peer review, and mentoring early-career researchers in oncology. His research skills are further strengthened by collaborations with international partners, where he has applied evidence-based approaches and contributed to comparative surgical studies. Overall, his diverse research competencies make him a global contributor to oncology innovation and academic development.

Awards and Honors

Assist. Prof. Dr. Hau Xuan Nguyen academic and clinical excellence has been recognized through numerous awards and honors. Notably, he received the Best Certificate at the Congress of the Asia Pacific Society of Thyroid Surgery in Japan for his outstanding research on the role of sentinel lymph node biopsy in thyroid carcinoma. His contributions to cancer surgery and research have also been acknowledged nationally through multiple awards for excellence in surgical oncology and publications in Vietnamese medical journals. He has co-authored influential oncology textbooks such as Oncology, Head and Neck Cancer, Thyroid Cancer, and Atlas of Thyroid Surgery, which are widely used by medical professionals and students in Vietnam. His international research collaborations have led to recognition in prestigious journals indexed in Scopus and Web of Science, affirming the global impact of his work. Additionally, his promotion to Associate Professor of Medicine represents a major academic honor, acknowledging his leadership in teaching, research, and clinical practice. Through these accolades, Assist. Prof. Dr. Hau Xuan Nguyen has built a strong academic reputation, establishing himself as a leader in surgical oncology in Vietnam and contributing meaningfully to global cancer care.

Publication Top Notes

  • Evaluate treatment results of stage II bladder cancer treatment with partial bladder surgery in National Cancer Hospital — 2014

  • Clinical features of stage III-IV tongue cancers treated by chemotherapy pre-surgery and/or radiotherapy — 2014

  • Evaluating the results of surgery for thyroid cancer at Hanoi Medical University Hospital — 2015

  • Evaluate the role of needle biopsy in the diagnosis of lung cancer before treatment — 2014

  • Evaluating the results of endoscopic surgery for benign thyroid at Hanoi Medical University Hospital — 2015

  • Evaluation of the results of the combination regimen of Gemcitabine with Cisplatin for the treatment of stage IV non-small-cell lung cancer — 2015

  • The results of the sentinel lymph node biopsy by methylene blue in thyroid cancer — 2017

Conclusion

Assist. Prof. Dr. Hau Xuan Nguyen exemplifies excellence in oncology, combining clinical innovation, research leadership, and academic mentorship. His pioneering work in transoral endoscopic thyroidectomy and sentinel lymph node biopsy has transformed surgical oncology practices in Vietnam and gained international recognition. With over 80 national and international publications, several oncology textbooks, and leadership roles in both academia and clinical care, he has significantly advanced the standards of cancer treatment and education. His strong research background, global collaborations, and focus on minimally invasive cancer therapies position him as a leader in the future of oncology. Beyond his academic achievements, his dedication to patient care and commitment to training the next generation of oncologists demonstrate his holistic approach to advancing medical science and society. Assist. Prof. Dr. Hau Xuan Nguyen achievements reflect a rare combination of innovation, leadership, and compassion, making him a deserving candidate for the Best Researcher Award. His future research will likely continue to push the boundaries of surgical oncology, enhancing cancer treatment outcomes not only in Vietnam but across the global medical community.

Maria Kourti | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Prof. Maria Kourti | Medicine and Dentistry | Best Researcher Award

Aristotle University of Thessaloniki | Greece

Prof. Maria Kourti is a distinguished academic and medical professional specializing in Pediatrics with a particular focus on Pediatric Hematology, Oncology, and Infectious Diseases. She currently serves as an Assistant Professor at Aristotle University of Thessaloniki, where she has been deeply involved in both teaching and research. Her career spans over two decades of excellence in clinical practice, scientific research, and international collaborations, with significant contributions to the understanding of childhood leukemia, drug resistance mechanisms, and pediatric infectious diseases. She has authored 73 publications indexed in PubMed, holds an h-index of 16, and has received over 1,000 citations, making her a recognized figure in her field. Prof. Kourti has combined clinical expertise with cutting-edge molecular and proteomic research, actively leading and participating in international multicenter studies and clinical trials. She is also extensively engaged in professional societies at the European and global levels, serving as a board member and committee leader in organizations dedicated to pediatric health. Alongside her academic achievements, she has contributed to medical education, mentorship, and health promotion initiatives, underlining her holistic approach to advancing both science and society. Her distinguished record makes her a highly respected leader in pediatric research and medicine.

Professional Profile

Scopus | ORCID 

Education

Prof. Maria Kourti pursued her entire academic journey at the Aristotle University of Thessaloniki, Greece, one of the most prestigious institutions in the country. She obtained her Medical Degree, laying the foundation for her career in pediatrics. With a strong interest in scientific research, she further advanced her education by earning a Master of Science (MSc) in Medical Research Technology, where she developed early expertise in biomedical investigations. Her passion for oncology and molecular medicine culminated in her Ph.D, with her thesis focused on the “Study of expression of multi-drug resistance genes in pediatric leukemia,” a topic that remains central to her research today. Her commitment to academic and clinical growth did not stop there, as she pursued advanced medical specialization, becoming Board Certified as a Specialist Pediatrician and later recognized as a Pediatric Infectious Disease Specialist. In the same year, she also completed a Post-Doctoral Fellowship in Proteomics in Childhood Leukemia, marking her continued dedication to translational research. This progression highlights her unique integration of medicine and science, equipping her with the academic depth and clinical expertise to make pioneering contributions in pediatric hematology, oncology, and infectious diseases.

Professional Experience

Prof. Maria Kourti has held several critical roles in clinical practice and academia, reflecting her dual expertise as a physician and researcher. she served as an Attending Physician in the Pediatric Oncology Department at Hippokration General Hospital, where she gained extensive clinical experience in treating children with hematological malignancies and solid tumors. Her expertise further deepened during her Pediatric Infectious Disease Fellowship at Aristotle University of Thessaloniki, based at Hippokration General Hospital. she worked as an Attending Physician in the 3rd Department of Pediatrics at Aristotle University, responsible for managing the Pediatric Hematology Unit, demonstrating her leadership in both patient care and academic responsibilities. she was appointed Assistant Professor of Pediatrics–Pediatric Hematology and Oncology at Aristotle University of Thessaloniki, where she continues to combine clinical duties with teaching and high-level research. Her responsibilities extend beyond the university, as she actively participates in national and international research programs, leading initiatives on childhood cancer, supportive care, and clinical trials. Through these roles, Prof. Kourti has developed a reputation for clinical excellence, academic leadership, and research innovation, making her a central figure in pediatric hematology and oncology in Greece and abroad.

Research Interests

Prof. Kourti’s research interests span the intersection of molecular biology, pediatric oncology, and infectious diseases, with a strong emphasis on improving treatment outcomes for children with cancer. Her doctoral and postdoctoral work centered on the molecular mechanisms of drug resistance in childhood leukemia, specifically the expression of multi-drug resistance genes and the application of proteomics to understand disease progression and treatment response. She has also been deeply engaged in genetic polymorphism studies, particularly in metabolic enzymes of carcinogenic substances in patients with acute leukemias and myelodysplastic syndromes. In addition to her oncology work, she has pursued significant research in pediatric infectious diseases, coordinating national efforts for the Greek Supportive Care Group and contributing to clinical research on antifungal therapies and novel antimicrobial strategies. Her interests also extend to large-scale clinical collaborations, where she has been both principal and sub-investigator in 15 multinational clinical trials addressing treatments for pediatric cancers and infections. This breadth of research demonstrates her commitment to translational medicine, bridging laboratory research with clinical applications. Her interests align with global health priorities, focusing on improving survival, reducing treatment toxicity, and enhancing supportive care in children with cancer.

Research Skills

Prof. Kourti possesses a strong foundation in molecular biology and clinical research methodologies, supported by advanced training and decades of practical application. Her technical expertise includes DNA and RNA extraction from blood and bone marrow samples, agarose gel electrophoresis, PCR, and RT-PCR, enabling her to investigate genetic and proteomic markers in pediatric leukemia. She has extensive experience with clinical trial design and implementation, having served as both a principal investigator and sub-investigator in numerous international studies, particularly within the SIOPE and SIOPEN networks. Her skills also extend to multidisciplinary collaboration, coordinating research teams across clinical and laboratory settings. In addition, Prof. Kourti has developed editorial and peer-review skills through her role as Guest Editor of special issues in international journals such as the Journal of Fungi and Diagnostics and as a reviewer for more than 10 medical journals. She also demonstrates expertise in data interpretation, publication writing, and conference presentation, with over 100 oral and poster presentations at national and international congresses. Her combined clinical and laboratory research skills, along with her organizational and editorial experience, make her a versatile and influential contributor to pediatric oncology and infectious disease research worldwide.

Awards and Honors

Throughout her career, Prof. Maria Kourti has received numerous awards and honors recognizing her excellence in research, teaching, and clinical practice. She has earned 10 major distinctions, including 3 scholarships from the National Scholarship Foundation (IKY), awarded for her academic performance and research potential. In addition, she has received 3 educational grants supporting her clinical and research training, as well as 6 first prizes for oral and poster presentations at both national and international medical congresses. These awards highlight not only her dedication to scientific inquiry but also her ability to effectively communicate her findings to diverse audiences. Beyond individual recognition, her leadership roles within professional societies such as the Hellenic Society for Social Pediatrics and Health Promotion, the National Pediatric Hematology and Oncology Society, and participation in European cooperative groups (SIOPE, ESPID, EXPeRT, ESCMID) further demonstrate the esteem in which she is held by the medical and scientific community. She has also contributed as a committee member for sustainability at ESPID, reflecting her commitment to long-term scientific advancement and ethical research practices. These honors collectively underscore her outstanding achievements and her influential role in pediatric medicine and research.

Publication Top Notes

  • Antifungal Use in Immunocompromised Children in Europe: A 12-Week Multicenter Weekly Point Prevalence Survey (CALYPSO) — 2025

  • A Global Analysis of Cases of Mucormycosis Recorded in the ECMM / ISHAM Zygomyco.net Registry from 2009 to 2022 — 2025

  • Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Research Network — 2025 — 3 citations

  • Addressing infectious challenges in pediatric cancer and hematopoietic cell transplantation: insights from the Umbrella Working Group — 2025

  • Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients — 2025

  • Planetary Health: What You Need to Know as a Pediatric Infectious Diseases Doctor — 2025

  • Successful Treatment of Disseminated Fusariosis in a 15-Month-old Boy With Refractory Acute Lymphoblastic Leukemia Using High-dose Voriconazole — 2024 — 1 citation

  • Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps — 2025

Conclusion

Prof. Maria Kourti exemplifies the qualities of a leading physician-scientist, with a career that integrates clinical expertise, innovative research, and academic leadership. Her groundbreaking work in childhood leukemia, infectious diseases, and pediatric oncology has advanced both scientific knowledge and clinical practice, directly impacting patient outcomes. With more than 73 peer-reviewed publications, extensive participation in international clinical trials, and leadership in national and European research groups, she has established herself as a key figure in the global pediatric research community. Her commitment to mentoring young scientists, active involvement in health promotion initiatives, and editorial contributions further enhance her academic profile. Looking ahead, Prof. Kourti is well-positioned to expand her research into global collaborations, increase her presence in high-impact journals, and take on greater leadership roles in shaping international pediatric oncology policies. Her career trajectory reflects not only past accomplishments but also significant potential for future contributions to medicine, making her a highly deserving candidate for continued recognition. In summary, Prof. Kourti’s lifelong dedication to advancing pediatric care and medical science positions her as an outstanding role model and leader in the field.

Guoguo Jin | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Assoc. Prof. Dr. Guoguo Jin | Medicine and Dentistry | Best Researcher Award

Deputy Director from Key Laboratory of Chronic Disease Health Management of Henan Province, China

Dr. Guoguo Jin is an accomplished biomedical researcher specializing in the chemical prevention of tumors. With a strong foundation in pathology and bioengineering, she has steadily developed a research career that bridges cancer biology and cardiovascular complications arising from oncological treatments. Her work delves into the molecular mechanisms underlying tumorigenesis, cardiotoxicity from chemotherapeutic agents, and the identification of therapeutic targets for various cancers, particularly esophageal, gastric, and colon carcinomas. Dr. Jin currently serves as the Deputy Director of both the Key Laboratory of Chronic Disease Health Management and the Department of Scientific Research and Discipline Construction at Fuwai Central China Cardiovascular Hospital. She has led several national and provincial-level research projects and has published extensively in top-tier journals. Her research contributions are complemented by multiple patents aimed at mitigating drug-induced cardiotoxicity. Recognized for her leadership and scientific acumen, she has received accolades such as the Young and Middle-aged Academic Leader title from the Health Commission of Henan Province. Overall, Dr. Jin’s work represents a compelling blend of scientific rigor, clinical relevance, and translational potential. Her continued efforts are likely to yield significant advancements in cancer therapy and patient care.

Professional Profile

Education

Dr. Guoguo Jin began her academic journey in bioengineering, earning her Master’s degree from the School of Bioengineering at Zhengzhou University in July 2011. This foundational training equipped her with critical insights into biomedical sciences and experimental techniques. She then pursued her doctoral studies in pathology and pathophysiology at the Basic Medical College of Zhengzhou University, receiving her Ph.D. in July 2017. During her doctoral program, she was selected for an international joint training opportunity and spent two years (2015–2017) at the prestigious Hormel Institute, University of Minnesota. There, she conducted in-depth research into the signal transduction pathways related to tumorigenesis and its prevention. Her time abroad not only enriched her technical competencies but also exposed her to cutting-edge methodologies in cancer biology. This combination of local and international academic training has laid a solid foundation for her ongoing research into tumor mechanisms and therapeutic strategies. Dr. Jin’s educational background reflects a trajectory of consistent academic excellence and scientific curiosity, establishing her as a capable and knowledgeable researcher in the fields of oncology and pathology.

Professional Experience

Dr. Guoguo Jin currently holds dual leadership roles at Fuwai Central China Cardiovascular Hospital, where she serves as Deputy Director of both the Key Laboratory of Chronic Disease Health Management of Henan Province and the Department of Scientific Research and Discipline Construction. Her professional responsibilities primarily involve overseeing tumor-related research and institutional academic development. Earlier in her career, she gained international experience at the Hormel Institute, University of Minnesota, where she focused on cancer signal transduction pathways. This exposure to high-impact research environments significantly influenced her approach to scientific inquiry. Throughout her career, Dr. Jin has successfully led multiple research projects funded at both national and provincial levels. These projects explore the molecular mechanisms of drug-induced cardiotoxicity, tumor progression, and the discovery of small-molecule inhibitors. Her clinical and translational research activities are closely integrated with her hospital’s goals, enhancing the relevance and impact of her findings. With a strong blend of laboratory management, project leadership, and interdepartmental coordination, Dr. Jin’s professional journey reflects her growth from a bench scientist to an influential figure in medical research administration. Her dual roles in scientific research and academic governance enable her to contribute meaningfully to both science and institutional progress.

Research Interest

Dr. Guoguo Jin’s primary research interest lies in the chemical prevention of tumors, with a focus on uncovering the molecular mechanisms that drive carcinogenesis and treatment-related complications. She is particularly interested in the pathways that regulate tumor initiation and progression in gastrointestinal cancers such as esophageal, gastric, and colon cancer. A significant portion of her work also explores the cardiotoxic effects of chemotherapeutic agents like osimertinib and doxorubicin, aiming to develop strategies to mitigate these adverse outcomes. Her recent studies have investigated the roles of signaling molecules such as WNK1, hnRNPU, AHCY-LDHA, and ZIP8 in cancer development and progression. Dr. Jin is also deeply involved in the identification and evaluation of small-molecule inhibitors and natural compounds like α-mangostin and curcumin for their anti-tumor efficacy. Her research bridges basic science and clinical application, positioning her work at the forefront of translational oncology. Through the development of targeted therapies and predictive biomarkers, she aims to improve both treatment outcomes and quality of life for cancer patients. This integrated focus on cancer biology and cardiotoxicity underlines her commitment to advancing personalized medicine in oncology.

Research Skills

Dr. Guoguo Jin possesses a wide array of research skills, especially in molecular and cellular biology techniques relevant to oncology. She is proficient in signal transduction analysis, gene expression profiling, histone modification studies, and functional validation of oncogenes and tumor suppressors. Her expertise extends to the use of in vitro and in vivo cancer models to study the efficacy and mechanisms of chemopreventive agents. She has demonstrated a high level of competence in utilizing molecular techniques such as Western blotting, qRT-PCR, immunohistochemistry, and chromatin immunoprecipitation assays. Her postdoctoral training at the Hormel Institute allowed her to master advanced techniques for dissecting signaling pathways in cancer. In addition to experimental skills, Dr. Jin has a solid foundation in project design, grant writing, and data analysis. She is also skilled in translating laboratory findings into potential therapeutic applications, as demonstrated by her patents. Moreover, her ability to manage multidisciplinary teams and coordinate with clinical departments enhances the practical relevance of her research. These competencies enable her to effectively lead complex biomedical projects from conceptualization to execution and dissemination.

Awards and Honors

Dr. Guoguo Jin has received multiple awards and honors that underscore her impact and promise in the field of medical research. In February 2024, she was selected as a Young and Middle-aged Academic Leader in Health and Wellness by the Health Commission of Henan Province, a recognition of her leadership in translational cancer research. Later that year, she was awarded a position in the National-Level Talent Cultivation Project for First-Class Discipline in Clinical Medicine at Zhengzhou University. Dr. Jin has also secured several competitive research grants, including the National Natural Science Foundation Youth Project, the Science and Technology Tackling Project by the Department of Science and Technology of Henan Province, and the Outstanding Young Talent Training Program for Health and Technology Innovation. Her innovative research on cancer prevention and cardiotoxicity has led to two patents, further highlighting her commitment to developing clinically relevant solutions. These accolades reflect not only her scientific excellence but also her dedication to advancing health outcomes through rigorous and applied research. The consistent support from national and provincial agencies illustrates her status as a leading figure in her domain.

Conclusion

Dr. Guoguo Jin exemplifies the qualities of a leading researcher with her focused expertise in chemical tumor prevention and translational oncology. Her well-rounded background—from robust academic training to leadership in high-impact research—positions her as a valuable contributor to both the scientific community and clinical practice. Her studies on molecular mechanisms of cancer progression and cardiotoxicity have not only expanded academic understanding but have also offered practical pathways for improving patient outcomes. Through national and provincial grants, influential publications, and patented innovations, she continues to push the boundaries of cancer therapy and prevention. While her research is already making a meaningful impact, future expansion into international collaborations and clinical trials could further elevate her contributions. Overall, Dr. Jin’s career is marked by scientific rigor, visionary leadership, and a commitment to translating research into real-world solutions. She is a highly deserving candidate for recognition through honors such as the Best Researcher Award and is likely to make even greater strides in cancer research in the years to come.

Publications Top Notes

  1. Title: STIP1 drives metabolic reprogramming in esophageal squamous cell carcinoma via AHCY-LDHA axis
    Authors: Jin G, Song Y, Yan M, Fang S, Shao Y, Zhao K, Liu M, Guo Q, Jia X, Zhang C, Wang Z, Liu K, Li X, Zhao S, Guo Z, Dong Z
    Year: 2025

  2. Title: hnRNPU-mediated pathogenic alternative splicing drives gastric cancer progression
    Authors: Jin G, Song Y, Fang S, Yan M, Yang Z, Shao Y, Zhao K, Liu M, Wang Z, Guo Z, Dong Z
    Year: 2025

  3. Title: ZIP8 modulates ferroptosis to drive esophageal carcinoma progression
    Authors: Yang Z, Zhao K, Li X, Yanzhang R, Zhang H, Yu Y, Yan M, Fang S, Li T, Li H, Chu X, Han S, Zhang Z, Teng J, Jin G, Guo Z
    Year: 2025

  4. Title: Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer
    Authors: Jin G, Yan M, Liu K, Yao K, Chen H, Zhang C, Yi Y, Reddy K, Gorja DR, Laster KV, Guo Z, Dong Z
    Year: 2020

  5. Title: Ginger extract inhibits c-MET activation and suppresses osteosarcoma in vitro and in vivo
    Authors: Yanzhang R, Yan M, Yang Z, Zhang H, Yu Y, Li X, Shen R, Chu X, Han S, Zhang Z, Teng J, Li H, Li T, Jin G, Guo Z
    Year: 2025

  6. Title: PDK1-mediated phosphorylation of USP5 modulates NF-κB signalling to enhance osteosarcoma growth
    Authors: Yang Z, Yu Z, Teng J, Yanzhang R, Yu Y, Zhang H, Jin G, Wang F
    Year: 2025

  7. Title: Precision therapy for cancer prevention by targeting carcinogenesis
    Authors: Jin G, Liu K, Guo Z, Dong Z*
    Year: 2024

  8. Title: Decrypting the Molecular Mechanistic Pathways Delineating the Chemotherapeutic Potential of Ruthenium-Phloretin Complex in Colon Carcinoma Correlated with the Oxidative Status and Increased Apoptotic Events
    Authors: Jin G, Zhao Z, Chakraborty T, et al.
    Year: 2020

  9. Title: Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma
    Authors: Zhao Z, Jin G, Yao K, Liu K, Liu F, Chen H, Wang K, Gorja DR, Reddy K, Bode A.M., Guo Z, Dong Z
    Year: 2019

  10. Title: Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway
    Authors: Li D, Wang G, Jin G, Yao K, Zhao Z, Bie L, Guo Y, Li N, Deng W, Chen X, Chen B, Liu Y, Luo S, Guo Z
    Year: 2019

Kumiko Tajima | Medicine and Dentistry | Women Researcher Award

Published on by WSA Awards

Dr. Kumiko Tajima | Medicine and Dentistry | Women Researcher Award

Manager from Gunma Central Hospital, Japan

Kumiko Tajima is a highly qualified medical professional with extensive experience in internal medicine and diabetes care. She graduated from Gunma University School of Medicine in 1992 and completed graduate studies at Gunma University Graduate School in 1999. With over two decades of clinical practice, she has served at several prominent medical institutions in Japan, including Gunma University School of Medicine, National Takasaki Hospital, and Gunma Prefectural Cardiovascular Center. Since 2014, she has been practicing at Gunma Central Hospital. Kumiko is recognized as a certified physician by the Japanese Society of Internal Medicine and specializes in general internal medicine and diabetes management. Her career is marked by a strong commitment to patient care, education, and specialized training, including roles as an instructor for medical training programs. She also serves vulnerable populations as a designated physician for disabilities and intractable diseases. While her clinical expertise is well documented, her research involvement is not explicitly detailed in the information available, suggesting a potential focus on clinical practice and medical education over research output. Nevertheless, her professional credentials and dedication to healthcare highlight her as a respected figure in the medical community.

Professional Profile

Education

Kumiko Tajima completed her formal education at Gunma University, one of Japan’s reputable institutions. She graduated from the Gunma University School of Medicine in 1992, where she acquired the foundational knowledge and clinical skills required to pursue a medical career. Following her medical degree, she advanced her expertise by completing graduate studies at Gunma University Graduate School in 1999. This postgraduate education likely included clinical research or advanced medical training, equipping her with enhanced knowledge in medical sciences. Her educational background provided a strong base for her subsequent clinical work and certifications in various medical specialties. Being an alumna of the same university for both undergraduate and graduate studies suggests continuity and depth in her academic preparation. Her education set the stage for her later roles in internal medicine, diabetes specialization, and her involvement in training programs. The rigorous training at Gunma University, known for its emphasis on both research and clinical practice, has likely influenced her professional trajectory, balancing patient care with medical education.

Professional Experience

Kumiko Tajima has accumulated significant clinical experience working in multiple prestigious medical institutions across Japan. Early in her career, she worked at Gunma University School of Medicine, which provided her with exposure to academic medicine and clinical research environments. She also served at National Takasaki Hospital, Tatebayashi Kosei Hospital, and Gunma Prefectural Cardiovascular Center, gaining diverse experience in patient care across various specialties and healthcare settings. Since 2014, she has been a key medical professional at Gunma Central Hospital, where she continues to provide specialized care in internal medicine and diabetes management. Throughout her career, she has been recognized for her expertise by multiple Japanese medical societies, reflected in her qualifications as a certified physician and specialist. She holds important roles such as a training instructor for diabetes care and general medical training, indicating her leadership in mentoring younger physicians. Additionally, her designation as a physician under the Welfare Act for the Physically Disabled and for intractable diseases highlights her involvement in public health and complex patient populations. Her extensive clinical roles demonstrate a strong foundation in both patient care and medical education.

Research Interests

While explicit details about Kumiko Tajima’s research interests are not provided in the information available, it is reasonable to infer that her research focus aligns closely with her clinical specialties—internal medicine and diabetes. Given her certifications and instructor roles within the Japan Diabetes Society, she likely engages with research related to diabetes management, treatment outcomes, and possibly public health aspects of chronic diseases. Her designation as a physician responsible for intractable diseases suggests potential interest in complex, difficult-to-treat conditions that may require innovative clinical approaches or translational research. Moreover, her role in general medical training indicates a probable interest in medical education research or clinical practice improvement. Without specific publications or ongoing research projects mentioned, her primary contributions may be in applying clinical knowledge to patient care and educating the next generation of physicians. If involved in research, it may focus on improving clinical protocols, diabetes education, or interdisciplinary care for chronic disease patients. Confirmation of such interests would strengthen her profile as a clinician-researcher.

Research Skills

Kumiko Tajima’s documented expertise suggests strong clinical skills particularly in internal medicine, diabetes care, and training future medical professionals. As a certified specialist and instructor in diabetes, she likely possesses advanced skills in managing complex cases, interpreting clinical data, and applying evidence-based medicine. Her role as an industrial physician and designated physician for the disabled reflects proficiency in occupational health and specialized patient management. Although there is no explicit mention of laboratory or bench research skills, her graduate education and clinical roles imply familiarity with clinical research methodologies, patient data analysis, and possibly clinical trial participation. Her instructional roles also suggest capabilities in curriculum development, clinical supervision, and medical education, which are important research-adjacent skills. If involved in research activities, these skills would be foundational for clinical studies, epidemiological research, or healthcare quality improvement projects. To enhance her research profile, further skills in scientific writing, grant applications, and collaboration in research networks would be beneficial.

Awards and Honors

The provided information does not list any specific awards or honors received by Kumiko Tajima. However, her qualifications as a certified physician by reputable Japanese medical societies, and her appointment as a specially appointed instructor for general medical training, indicate professional recognition within the medical community. These certifications and instructor roles can be seen as professional honors reflecting her expertise and dedication to clinical excellence and education. Additionally, her designation as a physician for intractable diseases and disabilities suggests recognition of her specialized skills and trust placed in her by public health authorities. While no formal awards are cited, her career achievements and appointments demonstrate a high level of respect and acknowledgment from her peers and regulatory bodies. Should she have received awards related to clinical innovation, research contributions, or teaching excellence, including these would enhance her profile for awards specifically focused on research.

Conclusion

Kumiko Tajima is an experienced and highly qualified medical professional with strong credentials in internal medicine and diabetes care. Her clinical expertise, long-standing service in multiple hospitals, and roles in medical training and specialized care demonstrate her dedication to both patient health and medical education. While she holds numerous certifications and leadership roles within professional medical societies, her profile lacks explicit information on research outputs, publications, or scientific contributions. For a Women Researcher Award focused on research excellence, evidence of active research involvement or scholarly achievements would be necessary to strengthen her candidacy. Nevertheless, her commitment to specialized clinical care, training, and vulnerable patient populations underscores her valuable role in the healthcare system. If supplemented by further details on her research activities, Kumiko Tajima could be a strong candidate. Currently, her profile is more aligned with clinical leadership and education, rather than research-centric recognition.

Publications Top Notes

  1. A case of SHORT syndrome with a novel genetic mutation diagnosed 19 years after the onset of diabetes

    • Authors: Kumiko Tajima, Yushi Hirota, Tomofumi Takayoshi, Wataru Ogawa

    • Year: 2025

  2. Medical Mystery: Abnormal Abdominal Radiograph — The Answer

    • Authors: Masahiko Kurabayashi, Kumiko Tajima

    • Year: 2007

  3. Medical Mystery — Abnormal Abdominal Radiograph

    • Authors: Kumiko Tajima, Masahiko Kurabayashi

    • Year: 2006

Agete Tadewos Hirigo | Medicine and Dentistry | Excellence in Research Award

Published on by WSA Awards

Mr. Agete Tadewos Hirigo | Medicine and Dentistry | Excellence in Research Award

Hawassa University, Ethiopia

Dr. Agete Tadewos Hirigo is an Assistant Professor at Hawassa University in Ethiopia, specializing in clinical chemistry and medical laboratory sciences. With a robust academic background and extensive research experience, he has significantly contributed to the fields of metabolic disorders, infectious diseases, and clinical diagnostics. Dr. Hirigo has authored over 40 peer-reviewed publications, reflecting his commitment to advancing medical science and improving healthcare outcomes in Ethiopia and beyond.

Professional Profile

Education

Dr. Hirigo’s academic journey began with a Diploma in Medical Laboratory Technology from Addis Ababa University in 2000. He then earned a BSc in Medical Laboratory Technology Sciences from Hawassa University in 2009. In 2012, he completed his MSc in Clinical Laboratory Sciences (Clinical Chemistry) at the University of Gondar. Currently, he is pursuing a PhD in Clinical Nutrition at Addis Ababa University, demonstrating his dedication to continuous learning and specialization in his field.

Professional Experience

Dr. Hirigo’s professional career spans over two decades. He started as a Senior Lab Technologist at Hawassa University Comprehensive Specialized Hospital from 2009 to 2011. He then served as an Expert Clinical Chemist from 2012 to 2015. From 2015 to 2019, he was a Lecturer at the School of Medical Laboratory Sciences, Hawassa University. Since July 2019, he has been serving as an Assistant Professor, where he is involved in lecturing, research, student supervision, and quality assurance in clinical chemistry laboratories.

Research Interests

Dr. Hirigo’s research interests are diverse and impactful. He focuses on metabolic disorders such as dyslipidemia and metabolic syndrome, particularly among HIV-infected and psychiatric patients. His work also encompasses the study of antiretroviral therapy effects, infectious diseases like hepatitis B and C, and public health issues such as hand hygiene practices among schoolchildren. His research aims to address critical health challenges in Ethiopia, contributing to evidence-based interventions and policies.

Research Skills

Dr. Hirigo possesses a comprehensive skill set in clinical laboratory sciences. His expertise includes laboratory diagnostics, clinical chemistry, and the use of statistical tools like SPSS for data analysis. He is proficient in designing and conducting cross-sectional and cohort studies, laboratory quality assurance, and instrument maintenance. His skills are instrumental in both academic research and practical laboratory settings, ensuring high standards of laboratory services and research outputs.

Awards and Honors

While specific awards and honors are not detailed in the available information, Dr. Hirigo’s extensive publication record and academic positions indicate recognition in his field. His involvement in significant research projects and collaborations with other institutions reflect his esteemed status in the academic and medical communities.

Conclusion

Dr. Agete Tadewos Hirigo exemplifies the qualities of a dedicated researcher and educator. His extensive experience, diverse research interests, and commitment to improving healthcare through science make him a valuable asset to the medical community. His work not only advances scientific knowledge but also has practical implications for public health in Ethiopia. Dr. Hirigo’s ongoing contributions continue to inspire and influence the field of clinical laboratory sciences.

Publications Top Notes

📘 1. Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation
Authors: SJ Connolly, G Karthikeyan, M Ntsekhe, A Haileamlak, A El Sayed, …
Journal: New England Journal of Medicine, 387(11), 978–988 (2022)
Citations: 200
🔬 Major randomized trial comparing rivaroxaban and vitamin K antagonists in RHD-AF.

📘 2. Hyperuricemia and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients at Hawassa University
Authors: SB Woyesa, AT Hirigo, TB Wube
Journal: BMC Endocrine Disorders (2017)
Citations: 96
🧪 Correlation study of uric acid levels and metabolic syndrome in diabetic patients.

📘 3. Prevalence of Dyslipidemia Among HIV-Infected Patients Using First-Line HAART
Authors: A Tadewos, Z Addis, H Ambachew, S Banerjee
Journal: AIDS Research and Therapy (2012)
Citations: 91
🩺 Comparative cross-sectional analysis in Southern Ethiopia.

📘 4. Burden of Metabolic Syndrome Among HIV-Infected Patients in Southern Ethiopia
Authors: DY Tesfaye, S Kinde, G Medhin, YC Megerssa, A Tadewos, E Tadesse, …
Journal: Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 8(2), 102–107 (2014)
Citations: 84
🧬 Assessment of metabolic complications among PLHIV on ART.

📘 5. Hepatitis B Virus Among Pregnant Women in Yirgalem Hospital, Ethiopia
Authors: A Amsalu, G Ferede, S Eshetie, A Tadewos, D Assegu
Journal: Journal of Pregnancy (2018), Article ID: 8435910
Citations: 78
👶 Implication of HBV screening for preventing mother-to-child transmission.

📘 6. The INVICTUS Rheumatic Heart Disease Research Program
Authors: G Karthikeyan, SJ Connolly, M Ntsekhe, A Benz, S Rangarajan, G Lewis, …
Journal: American Heart Journal, 225, 69–77 (2020)
Citations: 52
🫀 Study design for comparing rivaroxaban vs. VKA in RHD.

📘 7. Gender Influence in Metabolic Syndrome Among PLHIV on ART
Authors: AT Hirigo, DY Tesfaye
Journal: BMC Research Notes (2016)
Citations: 45
📊 Exploration of sex-based differences in ART-related metabolic issues.

📘 8. Length of Stay in Emergency Departments in Southern Ethiopia
Authors: GH Alemu, KG Negari, KM Rodamo, AT Hirigo
Journal: BMC Research Notes (2019)
Citations: 43
🏥 Study of variables influencing emergency department stay duration.

📘 9. Hand Washing Practices Among Primary Schoolchildren in Yirgalem
Authors: D Eshetu, T Kifle, AT Hirigo
Journal: Journal of Multidisciplinary Healthcare (2020), 759–768
Citations: 36
🧼 KAP study on hygiene practices among schoolchildren.

📘 10. Coinfections with Hepatitis B, C, and Syphilis Among HIV Patients
Authors: T Shimelis, Y Tassachew, A Tadewos, MW Hordofa, A Amsalu, …
Journal: HIV/AIDS – Research and Palliative Care
Citations: 33
⚕️ Cross-sectional data on coinfection rates in PLHIV.

 

Mohamed Nasreldin | Medicine and Dentistry | Excellence in Research Award

Published on by WSA Awards

Assist. Prof. Dr. Mohamed Nasreldin | Medicine and Dentistry | Excellence in Research Award

Consultant Nephrologist from Imam Abdulrahman Bin Faisal, Saudi Arabia

Dr. Mohamed Ahmed Nasreldin is an American consultant internist and nephrologist currently serving as Assistant Professor at King Fahad Hospital of the University (KFHU), Dammam, Saudi Arabia. With over 16 years of clinical experience, he has demonstrated exceptional competence in both internal medicine and nephrology, managing complex cases with compassion, precision, and interdisciplinary collaboration. Dr. Nasreldin holds a rich academic background complemented by international qualifications and fellowships, including the prestigious Fellow of the American Society of Nephrology (FASN). His work spans clinical care, teaching, and research, particularly in dialysis, kidney transplantation, and interventional nephrology. A committed educator, he has contributed significantly to medical education by tutoring nephrology fellows and mentoring residents and medical students. His fluency in Arabic, English, and Russian enhances his ability to connect across cultures and deliver impactful education and care. Dr. Nasreldin has received several awards and certificates of appreciation for his excellence in research presentations, academic contributions, and leadership in clinical practice. With a strong foundation in research and clinical trials, he has authored multiple peer-reviewed publications and continues to contribute to national and international nephrology forums. His career reflects a balanced dedication to patient care, clinical innovation, and academic leadership.

Professional Profile

Education

Dr. Mohamed Ahmed Nasreldin has pursued a comprehensive and international academic journey in medicine and nephrology. He holds a PhD in Clinical Nephrology (2016–2019) from UCN, USA, and a Clinical MD in Internal Medicine from Odessa State Medical University, Ukraine (2005–2009). He also earned an MBBS with honors in Medicine and Surgery from the same institution. His postgraduate education includes an MSc in Renal Medicine and a Postgraduate Diploma in Renal Medicine from the University of South Wales, UK. Dr. Nasreldin’s credentials also include the European Specialty Examination in Nephrology (ESENeph), jointly administered by the UEMS and the Royal College of Physicians, UK, along with a Fellowship from the American Society of Nephrology (FASN) awarded in 2019. His education is further supported by numerous certifications from globally recognized institutions, such as Johns Hopkins University (clinical research), the University of Leiden (kidney and pancreas transplantation), and the Royal College of Physicians, UK (renal medicine). In addition, he has completed specialized training in kidney pathology, gout management, and ADPKD treatment. This robust academic foundation not only underpins his clinical and research proficiency but also reflects his commitment to lifelong learning and evidence-based practice.

Professional Experience

With 16 years of experience in internal medicine and nephrology, Dr. Mohamed Nasreldin has established himself as a highly competent and dedicated clinician. He began his medical career with a residency program at Odessa State Medical University, where he gained extensive exposure to various subspecialties. Since 2009, he has been an integral part of the internal medicine department at King Fahad Hospital of the University (KFHU), Saudi Arabia. In this role, he manages both inpatient and outpatient care, including hemodialysis and peritoneal dialysis patients, and is actively involved in hospital consultations and on-call duties. Dr. Nasreldin’s clinical expertise covers a broad spectrum, from acute kidney injury and chronic kidney disease to renal transplantation and interventional nephrology. In addition to his clinical responsibilities, he plays a pivotal role in medical education and training. He tutors nephrology fellows, mentors residents, and delivers lectures to undergraduate and postgraduate students. His leadership in clinical care, education, and patient safety has been consistently recognized by peers and institutional authorities. Known for his problem-solving abilities under pressure, team collaboration, and organizational skills, Dr. Nasreldin continues to contribute significantly to both patient outcomes and the development of future nephrologists.

Research Interests

Dr. Mohamed Nasreldin’s research interests lie primarily in clinical nephrology, with a strong focus on dialysis modalities, renal transplantation, and interventional nephrology. He is particularly passionate about improving outcomes for patients on peritoneal dialysis and exploring patient-centered decision-making processes in renal care. His doctoral research examined the use of prophylactic antibiotics in end-stage renal disease (ESRD) patients undergoing colonoscopy while on automated peritoneal dialysis—a prospective randomized controlled trial that reflects his commitment to optimizing clinical protocols through evidence-based research. Dr. Nasreldin is also interested in transplant nephrology, including the management of acute and chronic allograft nephropathy, and the development of new catheter insertion techniques. His research extends to diabetes-related kidney disease, endothelial dysfunction in ischemic heart disease, and innovative strategies in nephrology education and practice. He has actively participated in clinical trials, presented findings at national and international conferences, and published research aimed at improving therapeutic outcomes in nephrology. As a mentor, he supervises clinical research for residents and fellows, fostering an academic environment that values inquiry and innovation. His dedication to research enhances his clinical practice, ensuring that patients benefit from the most current and effective medical interventions.

Research Skills

Dr. Nasreldin possesses a well-rounded set of research skills developed over more than a decade of conducting clinical investigations in internal medicine and nephrology. He is experienced in the design, monitoring, and execution of clinical trials, particularly randomized controlled studies that assess new interventions in renal care. His skills encompass the formulation of research hypotheses, patient recruitment and consent, data collection and analysis, and the interpretation of clinical findings for publication and presentation. Dr. Nasreldin is also proficient in guiding research as a supervisor and mentor, especially for nephrology fellows and internal medicine residents. His methodological strengths include statistical analysis, critical appraisal of the literature, and integration of research into clinical practice. Additionally, his ability to present research findings at scientific forums and publish in peer-reviewed journals underscores his communication and academic writing abilities. He is trained in research ethics and regulatory compliance, having completed a clinical research certificate from Johns Hopkins University. His involvement in various educational workshops and clinical symposiums enhances his collaborative research experience. These research skills have enabled him to contribute significantly to medical knowledge in nephrology, while also improving clinical decision-making and patient outcomes.

Awards and Honors

Dr. Mohamed Nasreldin has been recognized multiple times for his contributions to nephrology through awards and certificates of appreciation, reflecting both his clinical excellence and academic achievements. Notably, he received a Certificate of Appreciation at the First Gulf Peritoneal Dialysis Forum in Oman (2024) and won first place for poster presentation at the ISN-EMAN Update Congress in Nephrology, Dubai (2017). His oral presentation on acute kidney injury at the Saudi International Congress of Nephrology and Transplantation (2018) earned commendation, as did his role as a speaker at the International Conference of Diabetes and Its Complications in Baltimore (2017). He was honored by the nephrology division at King Fahad Hospital of the University for upholding high standards of care aligned with JCI requirements. Additionally, his participation in public awareness events, such as World Kidney Day, and academic initiatives like the 3rd Annual Research Day at King Saud University (2012), further illustrate his professional commitment. These accolades emphasize his role as a thought leader in nephrology, combining research, clinical practice, and public engagement. The consistent recognition from national and international platforms affirms Dr. Nasreldin’s impact on advancing kidney health and medical education.

Conclusion

Dr. Mohamed Ahmed Nasreldin stands out as a distinguished clinician, educator, and researcher in the field of nephrology, making him a strong candidate for the Excellence in Research Award. His extensive academic background, including a PhD in clinical nephrology and fellowship with the American Society of Nephrology, lays the foundation for his clinical acumen and research productivity. With over 16 years of experience, Dr. Nasreldin has shown exemplary commitment to improving patient outcomes, mentoring the next generation of physicians, and contributing to the scientific community. His research spans dialysis innovations, kidney transplantation, and interventional nephrology, all grounded in real-world clinical challenges. While his scholarly output could benefit from more high-impact journal publications and international collaborations, his existing contributions and active engagement in medical forums are noteworthy. Dr. Nasreldin’s work aligns closely with the criteria for the Excellence in Research Award—particularly through his original investigations, teaching impact, and patient-centered clinical innovations. His trajectory reflects a blend of practical application and academic inquiry, reinforcing his value to the nephrology community. Continued institutional support and broader research dissemination could further enhance his profile, making him not only a deserving recipient but also a future leader in academic nephrology.

Publications Top Notes

  1. An update on sickle cell nephropathy
    Author: A. Alhwiesh
    Journal: Saudi Journal of Kidney Diseases and Transplantation, 25(2), 249–265
    Year: 2014
    Citations: 54

  2. The use of SGLT2 inhibitors in peritoneal dialysis patients: a shade of light on dapagliflozin
    Authors: A.K. Alhwiesh, I.S. Abdul-Rahman, M.A. Nasreldin, A.M. Mohammed, …
    Journal: Archives of Nephrology and Urology, 5(1), 1–8
    Year: 2022
    Citations: 15

  3. Pregnancy in peritoneal dialysis and an infant with a ventricular septal defect
    Author: A. Alhwiesh
    Journal: Saudi Journal of Kidney Diseases and Transplantation, 26(1), 111–114
    Year: 2015
    Citations: 8

  4. A nephrologist dream of peritoneal dialysis catheter with zero migration: a multicenter prospective study
    Authors: A.K. Al‐Hwiesh, I.S. Abdul‐Rahman, J.C. Divino‐Filho, M.A. Nasreldin, …
    Journal: Therapeutic Apheresis and Dialysis, 28(1), 89–95
    Year: 2024
    Citations: 5

  5. A novel three cuff peritoneal dialysis catheter with low entry technique: three years single center experience
    Authors: A. Al-Hwiesh, I. Abdul-Rahman, N. Al-Audah, A. Noor, M. Nasreldin
    Journal: Urol Nephrol Open Access J, 4(5), 150–156
    Year: 2017
    Citations: 5

  6. The problem of pulmonary arterial hypertension in end-stage renal disease: can peritoneal dialysis be the solution
    Authors: A.K. Alhwiesh, I.S. Abdul-Rahman, A. Alshehri, A. Alhwiesh, M. Elnokeety, …
    Journal: BMC Nephrology, 23(1), 386
    Year: 2022
    Citations: 4

  7. Is percutaneous gastrostomy tube insertion contraindicated in adult peritoneal dialysis patients? A single-centre experience of three successful cases: it is time to revisit
    Authors: A. Alhwiesh, L. Alayoobi, H.A. Aljenaidi, K.M. Alshehabi, I. Abokaker Alghnimi, …
    Journal: The International Journal of Artificial Organs, 45(4), 438–441
    Year: 2022
    Citations: 2

  8. THE SAUDI PERITONEAL DIALYSIS CATHETER: MODIFIED CATHETER AND NEW TECHNIQUE: FAREWELL TO CATHETER MIGRATION
    Authors: A. Alhwiesh, M. Nasreldin
    Journal: Nephrology Dialysis Transplantation, 31
    Year: 2016
    Citations: 2

  9. The influence of increased peritoneal membrane surface area on dialysis adequacy
    Authors: A. Alhwiesh, S. Esam, I. Saeed, M. Ahmmed, F. Almohana
    Journal: Saudi Journal of Kidney Diseases and Transplantation, 22(4), 717–722
    Year: 2011
    Citations: 2

Ren Guibing | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Assoc. Prof. Dr. Ren Guibing | Medicine and Dentistry | Best Researcher Award

Associate Chief Physician from Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, China

Assoc. Prof. Dr. Ren Guibin is a distinguished oncologist and academic with an extensive background in the diagnosis and management of cancer. He currently serves as the Director of the Oncology Department at the Armed Police Characteristic Medical Center of the Chinese People’s Armed Police Force. With over 30 peer-reviewed publications, Dr. Guibin specializes in multidisciplinary tumor diagnosis and the systemic, comprehensive management of oncology cases. He holds the position of Associate Chief Physician and Associate Professor, and he also supervises graduate students. His significant involvement in various professional associations and committees demonstrates his leadership within the field of oncology. Dr. Guibin has gained recognition as a peer reviewer for the Armed Police Medical Journal and is a prominent figure in Chinese clinical oncology. His dedication to advancing cancer care through research and clinical practice is evident in his achievements and contributions to the oncology community.

Professional Profile

Education

Dr. Ren Guibin earned his medical degree (M.D.) from a prominent medical institution in China, where he developed a solid foundation in medicine. His academic journey continued with specialized training and clinical practice in oncology, which led him to achieve the position of Associate Chief Physician. His education, paired with extensive hands-on experience in the oncology department, laid the groundwork for his career as an educator and researcher in the field of cancer care. Throughout his career, Dr. Guibin has continuously sought further knowledge and professional development, furthering his understanding of both theoretical and practical aspects of oncology.

Professional Experience

Assoc. Prof. Dr. Ren Guibin’s professional experience spans over many years in the field of oncology. He holds the position of Director of the Oncology Department at the Armed Police Characteristic Medical Center of the Chinese People’s Armed Police Force. Dr. Guibin has gained recognition as an Associate Chief Physician, overseeing both clinical management and the medical education of students in oncology. His leadership role extends beyond the hospital, as he is actively involved in key professional societies. As a Master’s supervisor, Dr. Guibin plays a critical role in mentoring future professionals in oncology. His clinical experience and administrative leadership are complemented by his contributions to various committees within Chinese oncology associations.

Research Interests

Dr. Ren Guibin’s research interests focus primarily on the systemic and comprehensive management of oncology cases, specifically in the context of multidisciplinary tumor diagnosis and treatment. His research delves into innovative approaches for cancer diagnosis, treatment management, and patient care. He is dedicated to improving outcomes for oncology patients by exploring the full spectrum of cancer care, from prevention to advanced treatment strategies. His work reflects an integrated approach to understanding and treating cancer, encompassing clinical management and therapeutic innovations that benefit a diverse range of patients.

Research Skills

Assoc. Prof. Dr. Ren Guibin is highly skilled in the areas of cancer research, particularly in the multidisciplinary diagnosis of tumors. His research skills include expertise in systemic oncology management, focusing on comprehensive care strategies for cancer patients. Dr. Guibin is proficient in conducting clinical studies, developing treatment protocols, and analyzing complex clinical data to improve patient outcomes. He has substantial experience with both basic and applied oncology research, as well as the ability to manage large-scale, multidisciplinary research projects. Additionally, his peer-review activities further showcase his expertise in evaluating and contributing to the scientific literature on cancer care.

Awards and Honors

Throughout his distinguished career, Assoc. Prof. Dr. Ren Guibin has received various honors and recognition for his contributions to the field of oncology. These include his esteemed positions as a committee member of key oncology organizations in China, such as the Chinese Society of Clinical Oncology and the Tianjin Anti-Cancer Association. His work as a peer reviewer for the Armed Police Medical Journal also demonstrates his trusted position within the scientific community. These accolades reflect his significant contributions to both clinical practice and cancer research. His leadership and continuous dedication to advancing oncology have earned him respect within both national and international medical communities.

Conclusion

Assoc. Prof. Dr. Ren Guibin is a highly accomplished and respected figure in the field of oncology. His expertise in multidisciplinary tumor diagnosis, comprehensive cancer management, and his active involvement in academic and professional communities have positioned him as a leader in oncology care. His research has had a profound impact on advancing cancer treatment and improving patient outcomes. Dr. Guibin’s dedication to both clinical practice and education, combined with his leadership roles in various oncology associations, makes him an exceptional candidate for recognition. His continued contributions to the field promise to drive further progress in the fight against cancer, solidifying his legacy as an influential figure in the medical community.

Publication Top Note

  1. The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
    Authors: Wenqi Wu, Yanan Jiang, Donghui Xing, Guibing Ren, Zhigang Zhao
    Year: 2024
    Citations: 3